Last updated: February 13, 2026
Market Analysis and Price Projections for NDC 31722-0999
Product Overview
The National Drug Code (NDC) 31722-0999 corresponds to Tafasitamab (monotherapy), marketed as Monjuvi by MorphoSys and Incyte. Tafasitamab is a monoclonal antibody targeting CD19, approved by the FDA in 2020 for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It is used in combination with lenalidomide for adult patients who are ineligible for autologous stem cell transplant.
Market Landscape
1. Indication and Treatment Landscape
- Target Diseases: Primarily relapsed or refractory DLBCL.
- Standard Treatment: Historically, therapies include R-CHOP, CAR-T cell therapies, and other monoclonal antibodies.
- Treatment Gap: Limited options for patients ineligible for stem cell transplant or CAR-T.
2. Competitive Position
- Main Competitors:
- Rituximab-based regimens.
- Other CD19-targeting therapies (e.g., blinatumomab).
- CAR-T therapies like axicabtagene ciloleucel (Yescarta) and lisocabtagene maraleucel (Breyanzi).
- Market Entry Impact: Tafasitamab’s approval created a new antibody-based treatment choice, filling a validation niche for CD19-targeting agents in DLBCL.
3. Market Size & Penetration
- Prevalence: Approx. 28,000 new DLBCL cases annually in the U.S. (SEER data).
- Refractory/Relapsed Population: About 30-40% of new cases; representing a potential market of 8,400–11,200 patients annually.
- Treatment Uptake:
- Estimated initial market penetration was 10-15% in 2021-2022.
- Increased adoption estimated at 10% annually in subsequent years, contingent on clinical data and approval extensions.
Pricing Trends and Projections
1. Current Pricing
- List Price: Estimated at around $13,000 per dose.
- Dosing Schedule: Usually 21 mg/kg with a typical treatment course spanning 4-6 cycles, leading to approximate total treatment costs of $50,000–$100,000 per patient, depending on body weight and cycle duration.
- Net Price after Rebates & Payers: Likely 20-30% below list, reducing actual transaction price to approximately $9,100–$10,400 per dose.
2. Price Factors
- Market Competition: Limited direct competition among CD19 antibodies; CAR-T therapies are more expensive but offer longer remission.
- Reimbursement Environment: Managed care algorithms influence final reimbursement figures.
- Negotiation Power: Growth in market share depends on formulary acceptance and demonstration of clinical superiority or cost-effectiveness.
3. Future Price Projections (2023–2027)
| Year |
Price per Dose (Est.) |
Expected Market Penetration |
Estimated Annual Revenue (US) |
| 2023 |
$9,500 |
10% |
$250 million |
| 2024 |
$9,500 |
20% |
$470 million |
| 2025 |
$9,200 |
30% |
$700 million |
| 2026 |
$9,000 |
40% |
$950 million |
| 2027 |
$8,800 |
50% |
$1.2 billion |
Assumptions: Slight price decline due to increased biosimilar or generic pressures, broader market adoption, and competition from emerging therapies.
Key Revenue Drivers and Risks
- Adoption Growth: Physicians’ comfort with tafasitamab and evidence from ongoing trials.
- Reimbursement Landscape: Favorable coverage will accelerate market penetration.
- Competitive Dynamics: Entry of biosimilars or new competitors could compress prices.
- Regulatory Extensions: Additional approvals for other indications could expand market scope.
Summary of Market and Pricing Outlook
- The initial retail price of tafasitamab remains around $13,000 per dose but is discounted in real-world transactions.
- The market is in its growth phase, with revenues expected to reach approximately $1.2 billion by 2027.
- Price stability is linked to clinical differentiation, reimbursement policies, and competition from CAR-T and biosimilar products.
Key Takeaways
- NDC 31722-0999 (Tafasitamab) launched into a competitive but evolving DLBCL market.
- Current list price around $13,000 per dose, with net prices typically lower.
- Market penetration expected to grow steadily, potentially reaching $1 billion+ annual revenue by 2027.
- Pricing pressures will depend on competitive landscape, reimbursement, and clinical efficacy.
FAQs
Q1: How does tafasitamab compare with CAR-T therapies in efficacy?
- Tafasitamab offers an easier-to-administer outpatient option for certain relapsed/refractory DLBCL patients but generally has a different efficacy profile, often with lower remission rates compared to CAR-T, which can produce longer-lasting remissions in suitable patients.
Q2: What are the primary factors influencing tafasitamab’s price?
- Market competition, reimbursement policies, clinical trial results, and biosimilar development influence pricing.
Q3: Are biosimilars expected for tafasitamab?
- Biosimilar development could occur, especially if clinical or patent landscapes favor such entrants, which may reduce prices.
Q4: How might new indications affect market size?
- Approval for additional indications would expand patient eligibility, increasing market potential and revenue.
Q5: What is the potential for global expansion?
- Regulatory pathways exist in Europe and Asia; market entry depends on local approval and reimbursement models.
References
[1] FDA Label for Tafasitamab. U.S. Food and Drug Administration.
[2] SEER Cancer Statistics Review. National Cancer Institute.
[3] Market Research Reports on DLBCL treatments.
[4] Industry Price and Reimbursement Data.
[5] Biopharma Industry Forecast Publications.
